The use of patch tests in determining hypersensitivity to etanercept and infliximab

Archives of Dermatology

Volumn 144, Issue 8, 2008, Pages 1070-1071

  Lecluse, Lidian L A ^a   Piskin, Gamze ^b   Bos, Jan D ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ASCOMYCIN; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; SYNAPTOBREVIN; TACROLIMUS;

CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG ABSORPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; EDEMA; HUMAN; LETTER; MOLECULAR WEIGHT; PATCH TEST; PRIORITY JOURNAL; PSORIASIS; RASH; SENSITIVITY AND SPECIFICITY; SKIN TEST; TRANSDERMAL DRUG ADMINISTRATION;

EID: 49949107704     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.8.1070-b     Document Type: Letter

References (5)

1. Seneschal J, Lepreux S, Milpied B, Schaeverbeke T, Taieb A. Psoriasiform eruptions during anti-TNF-α treatment: psoriasis or not? Arch Dermatol. 2007; 143(12):1593-1595.
2. Seneschal J, Lepreux S, Bouyssou-Gauthier ML, et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm Venereol. 2007;87(1):77-80.
3. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002;138(9):1258-1259.
4. Scientific discussion. European Medicines Agency (EMEA) Web site. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/190199en6.pdf. Accessed February 12, 2008.
5. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-169.